PledPharma today announces that the MANAMI study is fully recruited
April 18, 2013
PledPharma AB Company Announcement PledPharma today announces that the MANAMI study is fully recruited All patients were included in the current small investigator initiated clinical phase IIa trial MANAMI, which examines a PLED substance in patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI). Stockholm, 2013-04-18 13:29 CEST (GLOBE NEWSWIRE) -- In the ongoing small investigator initiated clinical phase IIa trial MANAMI, which examines a PLED substance (mangafodipir) in patients with acute myocardial infarction undergoing coronary angioplasty (PCI), all twenty patients are now included. After analyzing the data, we expect to announce results during 2013. Preclinical studies show that PLED substances reduce permanent damage to the heart that often arises in the context of an acute myocardial infarction. Preclinical data also indicate that the use of PLED drugs in severe heart disease should not pose any safety risk. In the MANAMI study the PLED substance mangafodipir is currently being tested in a small number of patients with acute myocardial infarction. The study is conducted in the same manner as MANFOL study where mangafodipir was tested in a small number of cancer patients. The main purpose of the study is to show that PLED substances do not cause any obvious risk for patients undergoing PCI, and to get an indication if the PLED substances also reduces the damage to the heart - as shown in preclinical studies. For further information please contact: Jacques Näsström, CEO +46 737 130979 Jacques.nasstrom@pledpharma.se About PledPharma PledPharma is a Swedish specialty pharma company that develops PledOx™ for prevention of severe chemotherapy-induced side effects in cancer patients. Due to these side effects optimal treatment cannot be carried out. The current market for supportive cancer care is some SEK 72 billion. PledOx protects normal cells against oxidative stress. It belongs to a group of compounds named lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese SuperOxide Distmutase (MnSOD) – the most important endogenous cellular protectant against devastating oxidative stress. Oxidative stress is a condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of chemotherapy treatment. The company is also evaluating opportunities of using PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
